Tag: symposium
April 30, 2018
Are Thorium Reactors the Future of Nuclear Energy?
Thorium reactors hold promise as an alternative for uranium in the nuclear energy sector, but are they really a viable...
April 24, 2018
Vangold to Present at the Canadian Mining Symposium, London, UK
Vangold Mining Corp (TSXV:VAN; OTC:VGLDF) is pleased to announce that the Company will be participating in The Northern Miner —...
April 23, 2018
Vangold to Present at the Canadian Mining Symposium, London, UK
Vangold Mining Corp. (TSXV:VAN; OTC:VGLDF) ("Vangold" or the "Company") is pleased to announce that the Company will be participating in... March 26, 2018
Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine
Onconova Therapeutics (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, presented...
March 8, 2018
Gold Mining in Nunavut: Canada’s Frontier Mining Jurisdiction
Nunavut is Canada’s last frontier for mineral exploration. It rivals the size of Western Europe and hosts some of the... February 9, 2018
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update
Immunomedics (NASDAQ:IMMU) reported financial results for the second quarter ended December 31, 2017. The Company also highlighted recent key progress and... February 7, 2018
Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162... February 5, 2018
Argos Obtains Option to License PD1 Checkpoint Inhibitors
Argos Therapeutics (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision... January 19, 2018
TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105
TRACON Pharmaceuticals (NASDAQ:TCON), announced that positive initial clinical data from its ongoing Phase 1b/2 study of TRC105 and Nexavar® (sorafenib)...
December 13, 2017
